Agency is continuing efforts with manufacturers to address other IV fluid shortages
WEDNESDAY, Aug. 13, 2025 (HealthDay News) — The nationwide shortage of sodium chloride 0.9 percent intravenous (IV) saline has officially ended, according to the U.S. Food and Drug Administration.
FDA Commissioner Marty Makary, M.D., M.P.H., stated that the shortage has ended due to the combined efforts of the FDA, Administration for Strategic Preparedness and Response, and industry partners. The teams worked together to quickly boost manufacturing and stabilize the supply chain by enabling temporary IV solution imports, expediting manufacturing reviews, and extending product expiry dates.
The sodium chloride 0.9 percent injection shortage is resolved, and it will be removed from the FDA Drug Shortage Database; facilities are advised to use FDA-approved products when available. The FDA is continuing efforts with manufacturers to address other IV fluid shortages and is prioritizing reliable medical product availability.
“The FDA remains focused on doing all we can to help mitigate shortages and prevent them from occurring,” Makary said in a statement. “We will continue working diligently to monitor supply levels, anticipate potential disruptions, and support a robust, secure, and transparent supply chain for medical products.”
Acute Myeloid Leukemia Increasingly Impacting Older Adults Globally 
Emergency Diagnosis Linked to Worse Outcomes for Range of Conditions 
Small Change in Hours Benefits Emergency Physicians Working Night Shifts 
ED Boarding Time Varies Considerably Across Hospitals .jpg)
Warning Symptoms, Clinical History Can Predict Sudden Cardiac Arrest 
Protocol IDs Patients Who Can Be Treated While Seated in the ED 
Female Emergency Medicine Physicians Order More Tests, Admit More Patients 
Emergency Presentation of Cancer Common in Older Adults 
